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Beneficial effect of estrogen on 
nigrostriatal dopaminergic neurons 
in drug-naïve postmenopausal 
Parkinson’s disease
Yang Hyun Lee  1, Jungho Cha  2, Seok Jong Chung1, Han Soo Yoo1, Young H. Sohn1, 
Byoung Seok Ye1 & Phil Hyu Lee1,3
This study aimed to investigate the potential beneficial effects of estrogen on nigrostriatal 
dopaminergic neuron degeneration in postmenopausal drug-naïve Parkinson’s disease (PD). Based 
on the ratio of lifetime estrogen exposure length to the total length of the estrogen exposure and 
deprivation period, postmenopausal women with drug-naïve PD were divided into low (n = 31) and high 
(n = 31) estrogen exposure ratio groups. We performed a comparative analysis of the striatal dopamine 
transporter (DAT) availability between the two groups. Additionally, we evaluated the longitudinal 
change in the levodopa equivalent dose per month using a linear mixed model. The motor symptoms 
were more severe in the low estrogen exposure ratio group than in the high estrogen exposure 
ratio group (P = 0.016). PD patients in the two groups had significantly lower DAT availability on all 
striatal sub-regions except for ventral striatum than did age- and sex-matched normal controls. When 
comparing the two groups, PD patients in the low estrogen exposure ratio group exhibited significantly 
lower DAT availability in the posterior putamen (P = 0.024) and in the ventral putamen (P = 0.036) than 
those in the high estrogen exposure ratio group. The estimated monthly levodopa equivalent dose 
changes were 10.9 in the low estrogen exposure ratio group and 7.1 in the high estrogen exposure ratio 
group with a significant interaction between the two groups (P = 0.001). These in vivo data provide 
indirect evidence showing that estrogen may elicit a beneficial effect on nigrostriatal dopamine neurons 
in PD.
Epidemiologic studies have revealed that the prevalence of Parkinson’s disease (PD) is 1.5–2-fold lower in women 
than in men1,2, suggesting a possible protective influence of estrogen in predilection to the disease. Experimental 
evidences suggest that estradiol exerts neuroprotective effects on dopaminergic neurons and promotes dopamin-
ergic activity in the striatum3,4. Observational studies have indicated that increased length of estrogen exposure 
period was correlated with less severe PD symptoms and that the risk of developing PD was increased in women 
with experience of surgical menopause5,6. These data suggest that estrogen may have a protective effect on dopa-
minergic neurons in PD.
However, several studies have demonstrated that the incidence of PD in women appears to vary depending 
on the formulation and dose of hormone therapy, timing and length of dosing period, and history of surgical or 
natural menopause7,8. Furthermore, one animal study reported that long-term estrogen deprivation by prolonged 
ovariectomy in primates might be an important determinant in maintaining nigrostriatal dopamine neurons9. 
This finding suggests that not only the total length of lifetime estrogen exposure, but also the total period of estro-
gen deprivation might be crucial factors to modulate the loss of dopaminergic neurons.
Until now, the potential beneficial effects of estrogen on nigrostriatal dopaminergic degeneration in patients 
with PD have not been investigated using in vivo neuroimaging. In this study, according to the ratio of estrogen 
exposure length to the total length of the estrogen exposure and deprivation period (Eratio), we performed a 
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comparative analysis of the extent of presynaptic dopaminergic depletion by quantitatively measuring N-(3-[18F]
fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) positron emission tomography 
(PET) in postmenopausal women with drug-naïve PD. Additionally, we evaluated the influence of Eratio on the 
longitudinal requirement of dopaminergic medications in these patients.
Methods
Subjects. Subjects who visited the movement disorders clinic at Severance Hospital, Yonsei University from 
May 2010 to March 2018 were recruited from the database of the Yonsei Parkinson Center. The details of the 
enrollment of the study participants are illustrated in Fig. 1. Both 18F-FP-CIT PET scan and brain magnetic res-
onance imaging (MRI) were undergone within two months after initial visit to the clinic and before the start of 
dopaminergic medications. PD was diagnosed according to the clinical diagnostic criteria of the UK PD Society 
Brain Bank, and each subject exhibited decreased dopamine transporter (DAT) availability in the posterior 
putamen (PP) on the 18F-FP-CIT PET scans10. A total of 62 postmenopausal women out of 513 patients with 
drug-naïve PD were enrolled in this study.
To assess the severity of parkinsonian motor symptoms, the Unified Parkinson Disease Rating Scale Part III 
(UPDRS-III) was used. We calculated tremor and non-tremor scores for each patient according to the previously 
described method and classified patients into three subtypes: tremor dominant, akinetic-rigid, and mixed11. General 
cognition was scored using the K-MMSE score. The UPDRS-III and K-MMSE were measured at the initial visit to the 
clinic. Olfactory function was assessed with the Cross-Cultural Smell Identification Test (CCSIT), calculated as the sum 
of the correct responses. The Beck Depression Inventory (BDI) was administered to assess the severity of depression. 
The CCSIT and BDI were measured within one month after the first clinic visit. Age at menopause was estimated using 
the age at the last menstrual cycle or at the time of bilateral oophorectomy. Lifetime exposure to estrogen (estrogen 
exposure length) was the sum of difference between age at menopause and menarche (reproductive years) and years 
of estrogen replacement therapy (ERT) use12. The estrogen deprivation length was the difference between age at PD 
onset and estrogen exposure length. The estrogen exposure ratio (Eratio) was calculated by dividing estrogen exposure 
length by total length of estrogen exposure and deprivation period; (age at menopause − age at menarche + ERT dura-
tion)/(age at PD onset − age at menarche), as illustrated in Fig. S1. According to Eratio, patients were classified into two 
groups: the low Eratio group (n = 31) and the high Eratio group (n = 31) based on the distribution. The exclusion criteria 
included atypical parkinsonism, drug-induced parkinsonism, and evidence of focal brain lesions, diffuse white matter 
hyperintensities, or multiple lacunes in the basal ganglia as determined by MRI. In addition, we performed supple-
mentary analysis to evaluate age-related decline in DAT availability. Considering the mean age at PD onset in the low 
and high Eratio groups (67.6 years and 55.9 years, respectively), female and male de novo PD patients whose mean age 
at PD onset was comparable to each Eratio group were obtained from our previous cohort group13. The female PD group 
comprised of two subgroups whose mean age at PD onset was 68.0 years (PD-old [PD-O], n = 81) and 55.8 years 
(PD-young [PD-Y], n = 83). Similarly, the male PD group included two subgroups whose mean age at PD onset was 
67.4 years (PD-O, n = 86) and 55.9 years (PD-Y, n = 82). Normal controls consisted of 25 healthy female individuals 
with no neurological diseases. Considering the difference of mean ages at PD onset in low and high Eratio groups, we 
divided the control group (mean age, 61.4; n = 25) into two sub-groups whose mean ages were 67.4 years (control-old, 
n = 12) and 55.9 years (control-young, n = 13), which were comparable to mean ages at PD onset in the low and high 
Eratio groups. Then, we also performed a comparative analysis of DAT availability between the control-young and high 
Eratio groups as well as between the control-old and low Eratio groups, respectively. These subjects were selected from our 
institute and underwent 18F-FP-CIT PET and brain MRI. Eratio of the female PD-O and PD-Y groups was calculated by 
Figure 1. Study flow chart.
3Scientific RepoRts |         (2019) 9:10531  | https://doi.org/10.1038/s41598-019-47026-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
the information of reproductive factors obtained from the same questionnaire. This study was approved by the Yonsei 
University Severance Hospital ethical standards committee on human experimentation for experiments using human 
subjects and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of 
Helsinki. Informed consent was waived because this study reviewed pre-existing data, which was approved by the 
Institutional Review Board of Yonsei University Severance Hospital (IRB No. 4-2014-0637).
Longitudinal assessment of the changes in the levodopa equivalent dose. PD medications were 
prescribed after confirming decreased DAT availability in PP on the 18F-FP-CIT PET scans. The starting point of 
PD medications was at second clinic visit, which was within three months after the first visit. After diagnosis of 
PD, two movement disorder specialists (P.H.L. and Y.H.S.) adjusted the doses of PD medications for symptom 
control at 3–6-month intervals. At each visit, the doses of PD medication were checked, and the levodopa equiv-
alent dose (LED) was calculated based on previously described methodology14.
Quantitative analysis of the 18F-FP-CIT PET images. Image processing was performed using Statistical 
Parametric Mapping 12 (SPM12, Wellcome Department of Imaging Neuroscience, Institute of Neurology, 
London, England). For each patient, the reconstructed PET image was co-registered onto the corresponding 
MRI and normalized to the MNI152 template using normalization parameters defined from the corresponding 
MRI. Twelve volumes of interests (VOIs) of bilateral striatal sub-regions and one occipital VOI were drawn on 
the MNI152 template. The striatum was divided into right and left anterior/posterior caudate (AC/PC), ante-
rior/ventral/posterior putamen (AP/VP/PP), and ventral striatum (VS) as previously described (Supplementary 
Methods)13. In the supplementary analysis performed by including our previous PD cohort group, we used the 
methodology for analyzing 18F-FP-CIT PET images that had been employed in a previous study10.
Statistical analysis. Data are expressed as means ± standard deviations. Demographic and reproductive 
characteristics were compared using a student’s t-test for continuous variables, and Pearson’s χ2 test for cate-
gorical variables. An analysis of covariance was performed to compare DAT availability in striatal sub-regions 
after adjusting for age at PD onset and education duration. When comparing the specific to non-specific binding 
ratios (SNBRs) of the striatal sub-regions between groups, P values were further corrected for multiple com-
parisons using a false discovery rate method. The LED changes were estimated using a linear mixed model that 
included the following covariates: Eratio group, age at PD onset, and baseline DAT availability in PP, time, and 
Eratio group × time interaction. Pearson’s partial correlation analysis controlling age at PD onset and education 
duration was conducted to evaluate the relationship between Eratio values and mean SNBRs on both sides of each 
striatal subregion. The statistical analyses were performed with SPSS (version 23.0; IBM Corporation, Armonk, 
NY, USA), and results with a two tailed P value of <0.05 were considered statistically significant.
Results
Demographic and reproductive characteristics. Demographic and reproductive characteristics of the 
low and high Eratio groups and normal controls are provided in Table 1. As expected, PD patients in the low Eratio 
group were older at PD onset (67.6 ± 1.3 vs 55.9 ± 1.3, P < 0.001) than those in the high Eratio group. The educa-
tion duration was significantly longer in control-old and control-young groups than in the low and high Eratio 
groups. The low Eratio group had higher UPDRS-motor score (P = 0.016) than the high Eratio group. The proportion 
of PD subtypes did not differ between the two Eratio groups. The CCSI score was significantly lower in the low 
Eratio group than in the high Eratio group. Regarding reproductive characteristics, age at menopause in the low Eratio 
group was younger than in the high Eratio group (P = 0.002), whereas age at menarche, the proportion of ERT use, 
and surgical menopause did not differ between the two Eratio groups. The type of ERT formulation (estrogen-only 
or combined estrogen/progesterone therapy) was comparable between the two Eratio groups. Additionally, the 
timing at initiation of ERT was comparable between the groups. The estrogen exposure length was significantly 
shorter in the low Eratio group than in the high Eratio group (P < 0.001), and the total length of estrogen exposure 
and deprivation period was significantly longer in the low Eratio group than in the high Eratio group (P < 0.001).
SNBRs of PD subjects among the low and high Eratio groups and control groups. SNBRs for stri-
atal sub-regions in patients with the two Eratio groups and control groups are presented in Table 2 and Fig. 2. When 
comparing DAT availabilities between the control-young and high Eratio groups and between the control-old 
and low Eratio groups, PD patients in the low or high Eratio groups also showed significantly lower SNBRs in all 
sub-striatal regions, except for ventral striatum (Table 2). In a direct comparison between the two Eratio groups, 
SNBRs in the low Eratio group were significantly lower in PP (P = 0.024) and VP (P = 0.036) than in the high 
Eratio group. This difference was pronounced in the more affected side of putamen than in the less affected side. 
However, SNBRs in other striatal sub-regions exhibited no significant difference between the two Eratio groups. 
In addition, when classifying two groups not based on Eratio but on estrogen exposure length itself, there was no 
significant difference in SNBRs on any striatal sub-regions between low and high Eratio groups.
SNBRs of male and female PD-Y and PD-O patients. To evaluate whether aging influences striatal 
DAT availability, we further analyzed striatal SNBRs in PD-Y and PD-O subgroups of both sexes. Demographic 
characteristics of these subgroups are provided in Table S1. Except for education duration, clinical parameters 
including symptom duration, UPDRS-motor score, and K-MMSE score were comparable between male and 
female PD-Y and PD-O subgroups. Reproductive factors including the age at menarche, age at menopause, dura-
tion of ERT use, and estrogen exposure length exhibited no difference between the female PD-Y and PD-O sub-
groups. As expected, the Eratio was higher in the female PD-Y group relative to the female PD-O group because 
of the difference in ages at PD onset. In contrast to sub-striatal DAT availabilities between the two Eratio groups, 
SNBRs in all striatal sub-regions did not differ between male PD-Y and PD-O subgroups. Similarly, SNBRs in all 
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striatal sub-regions did not differ between the PD-Y and PD-O subgroups in female PD patients. SNBRs of all 
striatal sub-regions in the PD-Y and PD-O subgroups in both sexes are presented in Fig. 3 and Table S2.
Longitudinal changes in the LED during the follow-up period. The estimated monthly LED change 
was 10.9 in the low Eratio group and 7.1 in the high Eratio group, and there was significant interaction between the 
two groups and time in the linear mixed model, indicating that the monthly increase in the LED was significantly 
higher in the low Eratio group than in the high Eratio group (P = 0.001; Table 3).
Relationship between Eratio values and mean SNBRs on both sides of each striatal sub-region. 
Eratio values showed significant positive correlation with mean SNBRs on both sides of PP, VP, and AP (PP, 
P = 0.012; VP, P = 0.020; AP, P = 0.048). SNBRs in other striatal sub-regions exhibited no significant correlation 
with Eratio values (Table 4).
Demographic characteristics
Low Eratio group
(N = 31)
High Eratio group
(N = 31)
Control-old
(N = 12)
Control-young
(N = 13)
p value
(Low Eratio vs 
High Eratio)
p value
(Low Eratio vs 
Control-old)
p value
(High Eratio vs 
Control-young)
Age, y 67.61 ± 1.32a 55.87 ± 1.34a 67.37 ± 5.47 55.88 ± 3.28 <0.001 0.926 0.995
Female, No. (%) 31 (100%) 31 (100%) 12 (100.0%) 13 (100.0%) 1.000 1.000 1.000
Education 8.46 ± 0.80 9.75 ± 0.80 14.00 ± 3.38 13.54 ± 2.44 0.287 0.001 0.004
Symptom duration before PD diagnosis, y 1.50 ± 1.41 1.80 ± 2.08 0.505
UPDRS-III 22.54 ± 1.78 15.84 ± 1.61 0.016
PD motor subtype, n (%) 0.685
   Tremor-dominant 3 (9.6%) 6 (19.3%)
   Akinetic-rigid 10 (32.3%) 11 (35.5%)
   Mixed 18 (58.1%) 14 (45.2%)
CCSIT 6.54 ± 2.38 8.40 ± 2.36 0.004
BDI 12.42 ± 7.68 12.83 ± 6.89 0.840
K-MMSE 26.53 ± 0.45 27.22 ± 0.45 0.341
Follow-up duration, y 2.70 ± 2.63 2.91 ± 2.73 0.755
Total LED, mg 506.15 ± 208.67 350.36 ± 158.30 0.002
Levodopa dose, mg 382.76 ± 193.66 184.82 ± 166.44 <0.001
Reproductive characteristics
Age at menarche, y 15.94 ± 1.71 15.70 ± 1.74 0.597
Age at menopause, y 47.13 ± 5.33 51.37 ± 4.87 0.002
Reproductive period, y 31.19 ± 5.46 35.67 ± 5.06 0.002
Estrogen exposure length, y 31.51 ± 5.56 37.23 ± 4.32 <0.001
Estrogen deprivation length, y 20.17 ± 7.69 2.93 ± 5.26 <0.001
Estrogen exposure and deprivation length, y 51.68 ± 8.42 40.17 ± 6.32 <0.001
Eratio 0.62 ± 0.10 0.92 ± 0.087 <0.001
Ever use ERT, n (%) 0.740
   Yes 5 (16.1%) 6 (19.4%)
   No 26 (83.9%) 25 (80.6%)
Types of ERT, n (%) 0.740
   Use of estrogen only 3 (60.0%) 3 (50.0%)
   Use of combined
   estrogen/progesterone 2 (40.0%) 3 (50.0%)
Timing of ERT
initiation, n (%) 0.455
   Within 10 years from
   menopause 4 (80.0%) 6 (100.0%)
   After 10 years from
menopause 1 (20.0%) 0 (0.0%)
Duration ERT use, y 0.86 ± 1.25 6.00 ± 5.03 0.010
Surgical menopause, n (%) 0.159
   Yes 9 (29.0%) 4 (12.9%)
   No 22 (71.0%) 27 (87.1%)
Table 1. Baseline demographic and reproductive characteristics. Data are expressed as mean ± standard 
deviation or number (percentage). Abbreviations: UPDRS-III, Part III of the Unified Parkinson’s Disease Rating 
Scale; PD, Parkinson’s disease; K-MMSE, Korean version of Mini-Mental State Examination; CCSIT, Cross-
Cultural Smell Identification Test; BDI, Beck Depression Inventory; LED, Levodopa equivalent dose; Eratio, 
Estrogen exposure ratio; ERT, Estrogen replacement therapy. aAge at PD onset.
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Discussion
The present study investigated whether estrogen exerts neuroprotective effect on nigrostriatal dopaminergic neu-
rons in de novo PD patients using in vivo imaging. The major findings were as follows: (1) PD patients with higher 
Eratio exhibited less severe parkinsonian motor symptoms than those with lower Eratio. (2) PD patients in the high 
Eratio group had higher DAT availability in PP and VP than did those in the low Eratio group. Although the age at 
PD diagnosis was significantly lower in the high Eratio group relative to the low Eratio group, aging did not influ-
ence sub-striatal DAT availability in male or female PD subjects. (3) The longitudinal increase in the estimated 
monthly LED change was lower in the high Eratio group than in the low Eratio group. (4) Eratio values showed signif-
icant positive correlation with mean SNBRs on both sides of PP, VP, and AP.
In this study, we calculated Eratio based on not only lifetime estrogen exposure period, but also estrogen depri-
vation period. Previous studies have reported conflicting results on neuroprotective effects of estrogen exposure 
length on PD risk15,16. Several epidemiological studies reported that longer fertile life length is associated with 
decreased risk of PD in postmenopausal women17,18. On the other hand, it has been suggested that estrogen 
deprivation period after menopause could be a pivotal factor in the influence of estrogen effects on neurodegen-
erative disorders19. Likewise, our study showed that simple estrogen exposure period did not influence on DAT 
availability in any striatal sub-regions. Therefore, Eratio affected by both of the estrogen exposure and deprivation 
length could properly reflect estrogen-dependent pro-survival effect on dopaminergic neurons. Second, we per-
formed a quantitative analysis of DAT availability using individual MRI co-registration to improve the accuracy 
of sub-striatal DAT patterns instead of a standard 18F-FP-CIT PET template acquired from healthy controls10.
The present study demonstrated that the high Eratio group had higher DAT availability in PP and VP than did 
the low Eratio group, and this difference was more pronounced in the more affected side than in the less affected 
side. It is well known that PP and VP, as the sensorimotor striatum20, receive projections from the dopaminergic 
neurons in the ventrolateral substantia nigra, and are connected to the primary motor and somatosensory cor-
tices21. The results of the present study suggest that estrogen might exert a neuroprotective effect preferentially 
on nigrostriatal dopaminergic neurons that are primarily affected by PD pathology. Additionally, parkinsonian 
motor deficits were less severe in the high Eratio group relative to the low Eratio group, further supporting benefi-
cial effect of estrogen on nigrostriatal dopaminergic system. Regarding pro-survival effects of estrogen, estrogen 
might suppress harmful inflammatory reactions, protect nigrostriatal dopaminergic neurons by regulating gene 
transcription, and target compensatory responses in surviving neurons to restore striatal functionality22–24.
Our data revealed an age discrepancy between the two Eratio groups, since age at PD onset was included as a 
parameter when grouping patients. Since the end point of estrogen deprivation period is age at PD onset accord-
ing to the formula of Eratio, the low Eratio group with longer estrogen exposure and deprivation period had ten-
dency to have older age at PD onset. This is the reason why the low Eratio group appeared to have older age at PD 
Variables Side
Low Eratio group
(N = 31)
Control-old
(N = 12)
High Eratio group
(N = 31)
Control-young
(N = 13)
p valuea
(Low Eratio vs 
High Eratio)
p valuea
(Low Eratio vs 
Control-old)
p valuea
(High Eratio vs 
Control-young)
Anterior caudate
More affected side 2.26 ± 0.21 3.62 ± 0.64 2.60 ± 0.20 3.72 ± 0.62 0.424 <0.001 0.002
Less affected
side 2.59 ± 0.21 3.68 ± 0.66 2.77 ± 0.20 3.80 ± 0.61 0.793 0.003 0.009
Mean 2.48 ± 0.19 3.76 ± 0.61 2.79 ± 0.18 3.14 ± 0.31 0.334 0.001 0.003
Posterior caudate
More affected side 1.27 ± 0.14 2.19 ± 0.33 1.41 ± 0.13 2.14 ± 0.42 0.581 <0.001 0.002
Less affected
side 1.51 ± 0.15 2.27 ± 0.33 1.63 ± 0.14 2.24 ± 0.41 0.793 0.002 0.012
Mean 1.41 ± 0.13 2.23 ± 0.34 1.64 ± 0.13 2.19 ± 0.41 0.332 0.001 0.003
Anterior putamen
More affected side 2.38 ± 0.23 4.00 ± 0.50 2.77 ± 0.22 3.01 ± 0.38 0.424 <0.001 <0.001
Less affected
side 2.69 ± 0.20 4.08 ± 0.53 3.24 ± 0.20 4.12 ± 0.39 0.140 0.002 <0.001
Mean 2.54 ± 0.20 4.04 ± 0.52 3.16 ± 0.20 4.07 ± 0.38 0.096 0.001 <0.001
Posterior putamen
More affected side 0.89 ± 0.17 3.66 ± 0.34 1.57 ± 0.17 3.68 ± 0.33 0.027 <0.001 <0.001
Less affected
side 1.47 ± 0.17 3.74 ± 0.34 2.13 ± 0.17 3.80 ± 0.35 0.054 <0.001 <0.001
Mean 1.18 ± 0.18 3.70 ± 0.34 1.92 ± 0.18 3.74 ± 0.34 0.024 <0.001 <0.001
Ventral putamen
More affected side 1.44 ± 0.15 2.99 ± 0.31 2.02 ± 0.15 3.01 ± 0.34 0.027 <0.001 <0.001
Less affected
side 1.90 ± 0.14 3.14 ± 0.31 2.40 ± 0.14 3.11 ± 0.34 0.057 <0.001 <0.001
Mean 1.68 ± 0.15 3.06 ± 0.30 2.23 ± 0.15 3.06 ± 0.33 0.036 <0.001 <0.001
Ventral striatum
More affected side 2.54 ± 0.14 3.02 ± 0.42 2.73 ± 0.14 3.06 ± 0.32 0.424 0.042 0.114
Less affected
side 2.94 ± 0.16 3.15 ± 0.41 2.97 ± 0.15 3.21 ± 0.29 0.800 0.504 0.320
Mean 2.85 ± 0.16 3.08 ± 0.41 2.98 ± 0.15 3.14 ± 0.29 0.497 0.462 0.461
Table 2. SNBRs of PD subjects among the low and high estrogen exposure ratio groups and control groups. 
Data are expressed as mean ± standard deviation. Abbreviations: SNBRs, Specific to non-specific binding ratios; 
PD, Parkinson’s disease; Eratio, Estrogen exposure ratio. aFalse discovery rate-corrected p value of two group 
comparison.
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onset in this study. However, our study showed less motor severity and less dopamine depletion of sensorimotor 
striatum in the high Eratio group than in the low Eratio group, even though symptom durations before PD diag-
nosis were comparable. Generally, DAT availability in the striatum is decreased with age in normal subjects, at 
the mean rate of 5.3% per decade25,26. Considering that the difference in ages at PD onset between low and high 
Eratio groups is approximately ten years, our study showed 38.5% decline in mean SNBRs of posterior putamen 
and 19.3% decline in mean SNBRs of ventral putamen between the low and high Eratio groups. These percentages 
of decline in DAT availability between the groups were much greater than aging-related decline. Furthermore, 
in patients with PD, the effect of age on DAT availability in the striatum seems to be inconsistent; some reports 
demonstrated that the aging effects were significantly smaller in PD patients than in healthy subjects27, whereas 
others reported no aging effect on DAT availability in the putamen28–30. Therefore, to clarify whether beneficial 
effect of estrogen on dopaminergic neurons in the high Eratio group was secondary to the effect of age, we per-
formed supplementary analysis by comparing DAT availability in PD-O and PD-Y groups of both sexes whose 
mean ages were comparable to each Eratio group. However, DAT availabilities in PD-O and PD-Y groups of both 
sexes did not differ in any striatal sub-regions. Especially, all reproductive factors including the estrogen expo-
sure length were comparable between the female PD-O and PD-Y groups except for the mean ages at PD onset. 
Therefore, the difference of the estrogen exposure and deprivation length between the female PD-O and PD-Y 
groups was caused solely by the mean ages at PD onset, and subsequently resulted in the difference of Eratio values. 
Taken together, we can suggest that the effect of age alone does not lead to changes in DAT availabilities on the 
posterior and ventral putamen, but both estrogen exposure and deprivation length would have an impact on DAT 
availability selectively in the sensorimotor striatum.
Interestingly, the present study indicated that the longitudinal increase in the estimated monthly LED change 
during follow-up period was lower in the high Eratio group than in the low Eratio group. Although a longitudinal 
change in LED might not accurately reflect disease progression, LED appears to be indirectly associated with 
parkinsonian disability31. Regarding the prognostic role of estrogen, results of the present study may raise the 
possibility that estrogen can modulate longitudinal progression of parkinsonian motor deficits, although the 
difference in the longitudinal LED change may be secondary to the baseline difference in motor severity and 
sensorimotor striatal dopamine depletion.
Figure 2. Mean SNBRs of both sides of each striatal sub-region in PD subjects among the low and high Eratio 
groups and age- and sex-matched control groups. Mean SNBRs of both sides of each striatal sub-region in 
the low Eratio group were significantly lower in the PP and the VP compared to the high Eratio group. *P < 0.05. 
Abbreviations: SNBRs, Specific to non-specific binding ratios; PD, Parkinson’s disease; Eratio, estrogen exposure 
ratio; PP, posterior putamen; VP, ventral putamen.
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Figure 3. Mean SNBRs of both sides in striatal sub-regional activities in male and female patients with PD-Y 
and PD-O subgroups. Abbreviations: SNBRs, Specific to non-specific binding ratios; PD-O, PD-old; PD-Y,  
PD-young.
Estimated slope (standard error)
Low Eratio group p value High Eratio group p value Difference p value
Δ LED 10.9394 (0.8114) <0.001 7.0584 (0.8880) <0.001 3.8810 (1.2010) 0.001
Table 3. Longitudinal changes in LED across time in PD patients. The estimate (β) is the change in LED per 
month (Δ LED), i.e., positive value indicates the dose-up of PD medications. The effect of the PD subgroup (low 
estrogen exposure ratio group versus high estrogen exposure ratio group) on the change in LED across time 
was tested using the time x PD subgroup interaction term, and the low estrogen exposure ratio group exhibited 
a faster rate of dose-up of PD medications than the high estrogen exposure ratio group. Abbreviations: LED, 
levodopa-equivalent dose; PD, Parkinson’s disease; Eratio, Estrogen exposure ratio.
Variables (mean of both sides)
Eratio values
(N = 62) p value
Anterior caudate 0.219 0.112
Posterior caudate 0.205 0.138
Anterior putamen 0.271 0.048
Posterior putamen 0.339 0.012
Ventral putamen 0.316 0.020
Ventral striatum 0.149 0.283
Table 4. Correlation analysis of the SNBRs and estrogen exposure ratio values. Values are expressed as correlation 
coefficient. Abbreviations: SNBRs, Specific to non-specific binding ratios; Eratio, Estrogen exposure ratio.
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There were several limitations in this study. First, this study was based on a questionnaire answered by post-
menopausal participants who had to remember reproductive factors. Second, this study was based on a relatively 
small sample among a large cohort of more than 500 patients, which limits the generalization of our results pos-
sibly due to selection bias. However, we selected rigid inclusion and exclusion criteria to ascertain uniformity in 
clinical characteristics of enrolled patients, and strictly excluded those who could not remember their exact onset 
age of menarche and menopause to reduce recall bias as much as possible. In addition, because of small number of 
patients with surgical menopause or use of ERT, it was difficult to determine how these reproductive factors indi-
vidually affect each striatal DAT availability. Especially, based on the difference in duration of ERT use between 
the two Eratio groups, a further study focusing on patients with PD who received ERT would be needed to uncover 
this issue. Third, nigral neuron counts are not associated with striatal DAT availability in PD32. Therefore, caution 
should be exerted in the interpretation of our result that striatal DAT availability may reflect axonal dysfunction 
or DAT expression rather than the number of viable neurons.
In conclusion, the present study demonstrated that Eratio was closely coupled with nigrostriatal DAT availa-
bility and longitudinal maintenance of dopaminergic medications in patients with postmenopausal de novo PD. 
These in vivo data provide indirect evidence that estrogen may have beneficial properties in PD.
Data Availability
For purposes of replicating procedures and results, any qualified investigator can request anonymized data after 
ethics clearance and approval by all authors.
References
 1. Wooten, G. F., Currie, L. J., Bovbjerg, V. E., Lee, J. K. & Patrie, J. Are men at greater risk for Parkinson’s disease than women? J Neurol 
Neurosurg Psychiatry 75, 637–639 (2004).
 2. Van Den Eeden, S. K. et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157, 
1015–1022 (2003).
 3. Siani, F. et al. Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson’s Disease. Frontiers in 
neuroscience 11, 306 (2017).
 4. Al Sweidi, S. et al. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson’s 
disease. Journal of neuroendocrinology 24, 48–61 (2012).
 5. Cereda, E., Barichella, M., Cassani, E., Caccialanza, R. & Pezzoli, G. Reproductive factors and clinical features of Parkinson’s disease. 
Parkinsonism & related disorders 19, 1094–1099 (2013).
 6. Rocca, W. A. et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70, 
200–209 (2008).
 7. Popat, R. A. et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65, 
383–390 (2005).
 8. Liu, R. et al. Female reproductive factors, menopausal hormone use, and Parkinson’s disease. Movement disorders: official journal of 
the Movement Disorder Society 29, 889–896 (2014).
 9. Leranth, C. et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson’s 
disease and memory. J Neurosci 20, 8604–8609 (2000).
 10. Oh, M. et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive 
supranuclear palsy, and multiple-system atrophy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 53, 
399–406 (2012).
 11. Eggers, C., Kahraman, D., Fink, G. R., Schmidt, M. & Timmermann, L. Akinetic-rigid and tremor-dominant Parkinson’s disease 
patients show different patterns of FP-CIT single photon emission computed tomography. Movement disorders: official journal of the 
Movement Disorder Society 26, 416–423 (2011).
 12. Park, H. K. et al. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. 
Movement disorders: official journal of the Movement Disorder Society 33, 468–472 (2018).
 13. Yoo, H. S. et al. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease. 
European journal of nuclear medicine and molecular imaging 45, 423–431 (2018).
 14. Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement disorders: official 
journal of the Movement Disorder Society 25, 2649–2653 (2010).
 15. Rugbjerg, K., Christensen, J., Tjonneland, A. & Olsen, J. H. Exposure to estrogen and women’s risk for Parkinson’s disease: a 
prospective cohort study in Denmark. Parkinsonism & related disorders 19, 457–460 (2013).
 16. Lv, M. et al. Reproductive factors and risk of Parkinson’s disease in women: A meta-analysis of observational studies. Behavioural 
brain research 335, 103–110 (2017).
 17. Ragonese, P. et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62, 2010–2014 (2004).
 18. Gatto, N. M. et al. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism & related disorders 20, 
1149–1156 (2014).
 19. Rodriguez-Perez, A. I., Borrajo, A., Valenzuela, R., Lanciego, J. L. & Labandeira-Garcia, J. L. Critical period for dopaminergic 
neuroprotection by hormonal replacement in menopausal rats. Neurobiology of aging 36, 1194–1208 (2015).
 20. Parent, A. & Hazrati, L. N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res 
Brain Res Rev 20, 91–127 (1995).
 21. Lynd-Balta, E. & Haber, S. N. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum 
versus ventral striatum. Neuroscience 59, 625–640 (1994).
 22. Morale, M. C. et al. Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: glia dictates resistance versus 
vulnerability to neurodegeneration. Neuroscience 138, 869–878 (2006).
 23. Sawada, H. & Shimohama, S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neuroscience and 
biobehavioral reviews 24, 143–147 (2000).
 24. Gillies, G. E. & McArthur, S. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson’s 
disease: A contribution to sex-specific neuroprotection by estrogens. Hormones and behavior 57, 23–34 (2010).
 25. Lavalaye, J., Booij, J., Reneman, L., Habraken, J. B. & van Royen, E. A. Effect of age and gender on dopamine transporter imaging 
with [123I]FP-CIT SPET in healthy volunteers. European journal of nuclear medicine 27, 867–869 (2000).
 26. Kaasinen, V., Joutsa, J., Noponen, T., Johansson, J. & Seppanen, M. Effects of aging and gender on striatal and extrastriatal [123I]
FP-CIT binding in Parkinson’s disease. Neurobiology of aging 36, 1757–1763 (2015).
 27. Lee, C. S. et al. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson’s disease. Annals of nuclear medicine 28, 
874–879 (2014).
9Scientific RepoRts |         (2019) 9:10531  | https://doi.org/10.1038/s41598-019-47026-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 28. Lee, J. J., Ham, J. H., Lee, P. H. & Sohn, Y. H. Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinson’s Disease. 
Journal of movement disorders 8, 130–135 (2015).
 29. Booij, J., Bergmans, P., Winogrodzka, A., Speelman, J. D. & Wolters, E. C. Imaging of dopamine transporters with [123I]FP-CIT 
SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson’s disease. Synapse (New York, 
N.Y.) 39, 101–108 (2001).
 30. Eising, E. G. et al. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-
tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease. Journal of investigative medicine: the official 
publication of the American Federation for Clinical Research 45, 448–452 (1997).
 31. Olanow, C. W. Levodopa: effect on cell death and the natural history of Parkinson’s disease. Movement disorders: official journal of 
the Movement Disorder Society 30, 37–44 (2015).
 32. Saari, L. et al. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88, 
1461–1467 (2017).
Acknowledgements
This work was supported by Basic Science Research Program through the National Research Foundation of Korea 
(NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2016R1A2A2A05920131).
Author Contributions
The study was designed by Y.H. Lee and P.H. Lee. The statistical analysis was performed by Y.H. Lee, J.H. Cha, S.J. 
Chung, and H.S. Yoo. Drafting of the manuscript was performed by Y.H. Lee, J.H. Cha and P.H. Lee. The imaging 
data processing and analysis were carried out by J.H. Cha. The literature search, data interpretation, and revision 
of the manuscript were carried out by Y.H. Lee, J.H. Cha, S.J. Chung, H.S. Yoo, Y.H. Sohn, B.S. Ye, and P.H. Lee. 
P.H. Lee was involved in the final approval of the version to be published and takes responsibility for the integrity 
and accuracy of the data analyses.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47026-6.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
